{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:03:14Z","timestamp":1782871394932,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ABX advanced biochemical compounds GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The objective of this study was to compare the detection rates of [<jats:sup>18<\/jats:sup>F]PSMA-1007 and [<jats:sup>18<\/jats:sup>F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0.2\u20135.0\u00a0\u00b5g\/L).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a prospective, single-center (Radboudumc; Nijmegen, The Netherlands), comparative phase II diagnostic imaging study (NCT04239742). The main inclusion criteria were histologically proven adenocarcinoma of the prostate, BCR after radical treatment with two consecutive (rising) PSA values (0.2\u20135.0\u00a0\u00b5g\/L). Patients underwent both [<jats:sup>18<\/jats:sup>F]PSMA-1007 PET\/CT and [<jats:sup>18<\/jats:sup>F]Fluciclovine PET\/CT within two weeks. Both scans were blindly scored by three independent nuclear medicine physicians. Hereafter, a result per scan and region was generated by consensus. The primary outcome was to compare the detection rate on a patient and region level. Secondary objectives were to determine detection rate stratified for PSA value, inter-reader agreement, and SUV measurements. For lesion confirmation a composite reference score was established using follow-up data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data of fifty patients were included, median age of 71 (IQR: 67\u201374) years and median PSA value of 0.38 (IQR: 0.30\u20131.55) \u00b5g\/L. Detection rates were 68% (34\/50) for [<jats:sup>18<\/jats:sup>F]PSMA-1007 and 42% (21\/50) for [<jats:sup>18<\/jats:sup>F]Fluciclovine on a patient level (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Detection rates stratified for PSA value of [<jats:sup>18<\/jats:sup>F]PSMA-1007 in comparison with [<jats:sup>18<\/jats:sup>F]Fluciclovine were for PSA 0.2\u20130.5\u00a0\u00b5g\/L; 60.7% versus 25.0% (<jats:italic>p\u2009<\/jats:italic>=\u20090.002); and for PSA\u2009\u2265\u20090.5\u00a0\u00b5g\/L; 77.3% versus 63.6% (<jats:italic>p\u2009<\/jats:italic>=\u20090.250). There was a trend for higher inter-reader agreement with [<jats:sup>18<\/jats:sup>F]PSMA-1007. SUV<jats:sub>max<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was significantly higher for [<jats:sup>18<\/jats:sup>F]PSMA-1007 in comparison to [<jats:sup>18<\/jats:sup>F]Fluciclovine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In patients with early BCR of prostate cancer after radical surgery or radiotherapy, [<jats:sup>18<\/jats:sup>F]PSMA-1007 demonstrated a significantly higher detection rate than [<jats:sup>18<\/jats:sup>F]Fluciclovine. This is particularly relevant since earlier and more accurate detection of a BCR can guide salvage therapy into a tailored strategy which may improve outcomes.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: ClinicalTrials.gov, NCT 04239742. Registered 02 January 2020, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04239742\">https:\/\/clinicaltrials.gov\/study\/NCT04239742<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41824-024-00228-2","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T23:01:56Z","timestamp":1732662116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1670-2153","authenticated-orcid":false,"given":"Cato C.","family":"Loeff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"van Gemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan M.","family":"Priv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Hermsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Heijmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel J. R.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"4","key":"228_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.121.262412","volume":"63","author":"M Abghari-Gerst","year":"2022","unstructured":"Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D et al (2022) A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients. J Nucl Med 63(4):567\u2013572","journal-title":"J Nucl Med"},{"key":"228_CR2","unstructured":"Administration UFD. FDA approves new diagnostic imaging agent to detect recurrent prostate cancer 2016. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-diagnostic-imaging-agent-detect-recurrent-prostate-cancer"},{"issue":"2","key":"228_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M et al (2015) The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197\u2013209","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"228_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S et al (2017) Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 44(8):1258\u20131268","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"228_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13550-021-00783-w","volume":"11","author":"N Ahmadi Bidakhvidi","year":"2021","unstructured":"Ahmadi Bidakhvidi N, Laenen A, Jentjens S, Deroose CM, Van Laere K, De Wever L et al (2021) Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. EJNMMI Res 11(1):41","journal-title":"EJNMMI Res"},{"issue":"7","key":"228_CR6","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.3390\/cancers15072027","volume":"15","author":"L Bianchi","year":"2023","unstructured":"Bianchi L, Ceci F, Balestrazzi E, Costa F, Droghetti M, Piazza P et al (2023) PSMA-PET guided treatment in prostate cancer patients with oligorecurrent progression after previous salvage treatment. Cancers (Basel) 15(7):2027","journal-title":"Cancers (Basel)"},{"issue":"9","key":"228_CR7","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C et al (2019) (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20(9):1286\u20131294","journal-title":"Lancet Oncol"},{"issue":"3","key":"228_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, Leotta K, Eder M et al (2017) Preclinical evaluation of <sup>18<\/sup>F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. J Nucl Med 58(3):425\u2013431","journal-title":"J Nucl Med"},{"issue":"9","key":"228_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/MNM.0000000000001051","volume":"40","author":"B Chen","year":"2019","unstructured":"Chen B, Wei P, Macapinlac HA, Lu Y (2019) Comparison of 18F-Fluciclovine PET\/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Nucl Med Commun 40(9):940\u2013946","journal-title":"Nucl Med Commun"},{"issue":"5","key":"228_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249709","volume":"16","author":"JH Chung","year":"2021","unstructured":"Chung JH, Jeong JY, Lee JY, Song W, Kang M, Sung HH et al (2021) Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value. PLoS ONE 16(5):e0249709","journal-title":"PLoS ONE"},{"issue":"2","key":"228_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263\u2013282","journal-title":"Eur Urol"},{"issue":"5","key":"228_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B et al (2015) Evaluation of hybrid \u2076\u2078Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56(5):668\u2013674","journal-title":"J Nucl Med"},{"issue":"3","key":"228_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med 59(3):469\u2013478","journal-title":"J Nucl Med"},{"issue":"1","key":"228_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2017.07.011","volume":"8","author":"JD Evans","year":"2018","unstructured":"Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ (2018) Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol 8(1):28\u201339","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"228_CR15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY et al (2019) Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5(6):856\u2013863","journal-title":"JAMA Oncol"},{"key":"228_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M et al (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356\u2013387","journal-title":"Eur J Cancer"},{"issue":"4","key":"228_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W et al (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44(4):678\u2013688","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"228_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P et al (2019) Detection efficacy of (18)F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med 60(3):362\u2013368","journal-title":"J Nucl Med"},{"issue":"2","key":"228_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","volume":"45","author":"B Grubm\u00fcller","year":"2018","unstructured":"Grubm\u00fcller B, Baltzer P, D\u2019Andrea D, Korn S, Haug AR, Hacker M et al (2018) (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy\u2014diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging 45(2):235\u2013242","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"228_CR20","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, M\u00fcller J (2021) Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging 48(13):4483\u20134494","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"228_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.eururo.2015.12.051","volume":"70","author":"A Herlemann","year":"2016","unstructured":"Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C et al (2016) (68)Ga-PSMA positron emission tomography\/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 70(4):553\u2013557","journal-title":"Eur Urol"},{"issue":"10231","key":"228_CR22","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208\u20131216","journal-title":"Lancet"},{"issue":"6","key":"228_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR (2019) Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med 60(6):786\u2013793","journal-title":"J Nucl Med"},{"issue":"10288","key":"228_CR24","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","volume":"397","author":"AB Jani","year":"2021","unstructured":"Jani AB, Schreibmann E, Goyal S, Halkar R, Hershatter B, Rossi PJ et al (2021) (18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial. Lancet 397(10288):1895\u20131904","journal-title":"Lancet"},{"issue":"3","key":"228_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0090-4295(02)02411-1","volume":"61","author":"CJ Kane","year":"2003","unstructured":"Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB et al (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61(3):607\u2013611","journal-title":"Urology"},{"issue":"5","key":"228_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2967\/jnumed.117.190157","volume":"58","author":"C Kesch","year":"2017","unstructured":"Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL (2017) (68)Ga or (18)F for prostate cancer imaging? J Nucl Med 58(5):687\u2013688","journal-title":"J Nucl Med"},{"issue":"5","key":"228_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4111\/icu.2017.58.5.307","volume":"58","author":"J Kim","year":"2017","unstructured":"Kim J, Park JS, Ham WS (2017) The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer. Investig Clin Urol 58(5):307\u2013316","journal-title":"Investig Clin Urol"},{"issue":"8","key":"228_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2967\/jnumed.122.265077","volume":"64","author":"PH Kuo","year":"2023","unstructured":"Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J et al (2023) A VISION substudy of reader agreement on (68)Ga-PSMA-11 PET\/CT scan interpretation to determine patient eligibility for (177)Lu-PSMA-617 radioligand therapy. J Nucl Med 64(8):1259\u20131265","journal-title":"J Nucl Med"},{"issue":"1","key":"228_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159\u2013174","journal-title":"Biometrics"},{"issue":"2","key":"228_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/a-1759-1603","volume":"61","author":"T Lengana","year":"2022","unstructured":"Lengana T, Lawal I, Janse Van Rensburg C, Mokoala K, Moshokoa E, Mazibuko S et al (2022) The diagnostic performance of 18F-PSMA-1007 PET\/CT in prostate cancer patients with early recurrence after definitive therapy with a PSA < 10 ng\/ml. Nuklearmedizin 61(2):120\u2013129","journal-title":"Nuklearmedizin"},{"issue":"1","key":"228_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/iju.IJU_355_18","volume":"35","author":"BZ McCormick","year":"2019","unstructured":"McCormick BZ, Mahmoud AM, Williams SB, Davis JW (2019) Biochemical recurrence after radical prostatectomy: current status of its use as a treatment endpoint and early management strategies. Indian J Urol 35(1):6\u201317","journal-title":"Indian J Urol"},{"issue":"7","key":"228_CR32","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s00259-022-05693-0","volume":"49","author":"C Mingels","year":"2022","unstructured":"Mingels C, Bohn KP, Rominger A, Afshar-Oromieh A, Alberts I (2022) Diagnostic accuracy of [(18)F]PSMA-1007 PET\/CT in biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 49(7):2436\u20132444","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"228_CR33","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1097\/RLU.0000000000000849","volume":"40","author":"C Nanni","year":"2015","unstructured":"Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L et al (2015) 18F-fluciclovine PET\/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET\/CT. Clin Nucl Med 40(8):e386\u2013e391","journal-title":"Clin Nucl Med"},{"issue":"9","key":"228_CR34","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00259-016-3329-1","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F et al (2016) (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET\/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging 43(9):1601\u20131610","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"228_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.nucmedbio.2011.06.008","volume":"39","author":"S Oka","year":"2012","unstructured":"Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y (2012) Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol 39(1):109\u2013119","journal-title":"Nucl Med Biol"},{"issue":"4","key":"228_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2967\/jnumed.122.264743","volume":"64","author":"P Olivier","year":"2023","unstructured":"Olivier P, Giraudet AL, Skanjeti A, Merlin C, Weinmann P, Rudolph I et al (2023) Phase III study of (18)F-PSMA-1007 versus (18)F-Fluorocholine PET\/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized. Crossover multicenter study. J Nucl Med 64(4):579\u2013585","journal-title":"J Nucl Med"},{"issue":"5","key":"228_CR37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446\u2013453","journal-title":"J Clin Oncol"},{"issue":"6","key":"228_CR38","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.eururo.2013.08.013","volume":"65","author":"D Pfister","year":"2014","unstructured":"Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S et al (2014) Early salvage radiotherapy following radical prostatectomy. Eur Urol 65(6):1034\u20131043","journal-title":"Eur Urol"},{"issue":"2","key":"228_CR39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41391-022-00544-3","volume":"26","author":"A Pozdnyakov","year":"2023","unstructured":"Pozdnyakov A, Kulanthaivelu R, Bauman G, Ortega C, Veit-Haibach P, Metser U (2023) The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostat Dis 26(2):240\u2013248","journal-title":"Prostate Cancer Prostat Dis"},{"issue":"11","key":"228_CR40","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2967\/jnumed.116.173492","volume":"57","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G et al (2016) Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med 57(11):1713\u20131719","journal-title":"J Nucl Med"},{"issue":"1","key":"228_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.119.229187","volume":"61","author":"I Rauscher","year":"2020","unstructured":"Rauscher I, Kr\u00f6nke M, K\u00f6nig M, Gafita A, Maurer T, Horn T et al (2020) Matched-pair comparison of (68)Ga-PSMA-11 PET\/CT and (18)F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med 61(1):51\u201357","journal-title":"J Nucl Med"},{"key":"228_CR42","doi-asserted-by":"publisher","first-page":"37534","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D, Fornarini G, Cioffi M, Laudicella R et al (2024) The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging 51:37534","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"228_CR43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","volume":"73","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA (2018) PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol 73(4):485\u2013487","journal-title":"Eur Urol"},{"issue":"5","key":"228_CR44","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00259-015-3251-y","volume":"43","author":"CO Sahlmann","year":"2016","unstructured":"Sahlmann CO, Meller B, Bouter C, Ritter CO, Str\u00f6bel P, Lotz J et al (2016) Biphasic \u2076\u2078Ga-PSMA-HBED-CC-PET\/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging 43(5):898\u2013905","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"228_CR45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ijrobp.2020.01.050","volume":"107","author":"AF Scarsbrook","year":"2020","unstructured":"Scarsbrook AF, Bottomley D, Teoh EJ, Bradley KM, Payne H, Afaq A et al (2020) Effect of (18)F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial. Int J Radiat Oncol Biol Phys 107(2):316\u2013324","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"228_CR46","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3(1):81\u201385","journal-title":"Clin Cancer Res"},{"issue":"23","key":"228_CR47","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","volume":"299","author":"BJ Trock","year":"2008","unstructured":"Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299(23):2760\u20132769","journal-title":"JAMA"},{"issue":"2","key":"228_CR48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41391-019-0194-6","volume":"23","author":"E Witkowska-Patena","year":"2020","unstructured":"Witkowska-Patena E, Gi\u017cewska A, Dziuk M, Mi\u015bko J, Budzy\u0144ska A, Wal\u0119cka-Mazur A (2020) Diagnostic performance of 18F-PSMA-1007 PET\/CT in biochemically relapsed patients with prostate cancer with PSA levels \u2264 2.0\u00a0ng\/ml. Prostate Cancer Prostatic Dis 23(2):343\u2013348","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"228_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","volume":"1","author":"GL Wright Jr","year":"1995","unstructured":"Wright GL Jr, Haley C, Beckett ML, Schellhammer PF (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1(1):18\u201328","journal-title":"Urol Oncol"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00228-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-024-00228-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00228-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:02:39Z","timestamp":1732665759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-024-00228-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["228"],"URL":"https:\/\/doi.org\/10.1186\/s41824-024-00228-2","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki (version 2013) and approved by the medical ethical committee Arnhem-Nijmegen. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BP received research support from Novartis, ABX advanced biochemical compounds GmbH, JN received research support from Novartis, ABX advanced biochemical compounds GmbH, MJ received research support from Novartis, ABX advanced biochemical compounds GmbH. RH received consultancy fees from ABX advance biochemical compounds GmbH and Blue Earth Diagnostics. No other potential conflicts of interest relevant to this article exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}